124 related articles for article (PubMed ID: 25270946)
1. False dawn for cystic fibrosis disease modifiers?
Holmes D
Nat Rev Drug Discov; 2014 Oct; 13(10):713-4. PubMed ID: 25270946
[No Abstract] [Full Text] [Related]
2. Ivacaftor.
Davis PB; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2012 Apr; 11(5):349-50. PubMed ID: 22543461
[No Abstract] [Full Text] [Related]
3. First cystic fibrosis drug advances towards approval.
Sheridan C
Nat Biotechnol; 2011 Jun; 29(6):465-6. PubMed ID: 21654649
[No Abstract] [Full Text] [Related]
4. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label.
Ratner M
Nat Biotechnol; 2017 Jul; 35(7):606. PubMed ID: 28700545
[No Abstract] [Full Text] [Related]
5. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
Kaiser J
Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
[No Abstract] [Full Text] [Related]
6. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
Mayer M
Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
[No Abstract] [Full Text] [Related]
7. Cystic fibrosis drug Vertex's latest triumph.
Ledford H
Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
[No Abstract] [Full Text] [Related]
8. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
9. Aquagenic wrinkling of the palms in a patient with cystic fibrosis.
Grasemann H; Ratjen F; Solomon M
N Engl J Med; 2013 Dec; 369(24):2362-3. PubMed ID: 24328486
[No Abstract] [Full Text] [Related]
10. FDA OKs first in vitro route to expanded approval.
Kingwell K
Nat Rev Drug Discov; 2017 Sep; 16(9):591-592. PubMed ID: 28860581
[No Abstract] [Full Text] [Related]
11. Ivacaftor, vismodegib, and ingenol mebutate.
Hussar DA; Eckel SP
J Am Pharm Assoc (2003); 2012; 52(3):418-22. PubMed ID: 22618984
[No Abstract] [Full Text] [Related]
12. Transformative mutation specific pharmacotherapy for cystic fibrosis.
Sanders DB; Farrell PM
BMJ; 2012 Jan; 344():e79. PubMed ID: 22232540
[No Abstract] [Full Text] [Related]
13. Straight talk with... Robert Beall. Interviewed by Elie Dolgin.
Beall R
Nat Med; 2012 Mar; 18(3):335. PubMed ID: 22395687
[No Abstract] [Full Text] [Related]
14. Targeting a cystic fibrosis mutation opens door for personalized treatment.
Morrow T
Manag Care; 2012 Apr; 21(4):53-4. PubMed ID: 22590787
[No Abstract] [Full Text] [Related]
15. New cystic fibrosis drug paves the way for orphan diseases.
Cooney D
Lancet Respir Med; 2013 Apr; 1(2):104. PubMed ID: 24429084
[No Abstract] [Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
17. The organoid architect.
Sinha G
Science; 2017 Aug; 357(6353):746-749. PubMed ID: 28839056
[No Abstract] [Full Text] [Related]
18. Ivacaftor (Kalydeco) for cystic fibrosis.
Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233
[No Abstract] [Full Text] [Related]
19. CFTR potentiators: not an open and shut case.
Clancy JP
Sci Transl Med; 2014 Jul; 6(246):246fs27. PubMed ID: 25101884
[TBL] [Abstract][Full Text] [Related]
20. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding.
Cohen D; Raftery J
BMJ; 2014 Feb; 348():g1445. PubMed ID: 24523379
[No Abstract] [Full Text] [Related]
[Next] [New Search]
